{"protocolSection": {"identificationModule": {"nctId": "NCT00420511", "orgStudyIdInfo": {"id": "065-00"}, "organization": {"fullName": "Samuel Lunenfeld Research Institute, Mount Sinai Hospital", "class": "OTHER"}, "briefTitle": "Beta-Cell Function and Sitagliptin Trial (BEST)", "officialTitle": "A Randomized Controlled Pilot Study Assessing the Effect of Sitagliptin on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes", "acronym": "BEST"}, "statusModule": {"statusVerifiedDate": "2011-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-01-10", "studyFirstSubmitQcDate": "2007-01-10", "studyFirstPostDateStruct": {"date": "2007-01-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-06-24", "resultsFirstSubmitQcDate": "2011-12-20", "resultsFirstPostDateStruct": {"date": "2011-12-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-12-28", "lastUpdatePostDateStruct": {"date": "2012-01-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Bernard Zinman", "investigatorTitle": "Director, Leadership Sinai Centre for Diabetes", "investigatorAffiliation": "Samuel Lunenfeld Research Institute, Mount Sinai Hospital"}, "leadSponsor": {"name": "Samuel Lunenfeld Research Institute, Mount Sinai Hospital", "class": "OTHER"}, "collaborators": [{"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). The investigators propose a double-blind, randomized controlled pilot study comparing the effect of sitagliptin (a novel anti-diabetic drug with beta-cell protective potential) versus placebo, on the preservation of beta-cell function over one year in patients with T2DM on metformin, the first-line agent for the treatment of T2DM (ie. the study groups will be (i) sitagliptin and metformin versus (ii) placebo and metformin). This study may demonstrate an important beta-cell protective capacity of sitagliptin.\n\nHypothesis: In patients with T2DM on metformin, treatment with the DPP-IV inhibitor sitagliptin will preserve pancreatic beta-cell function.", "detailedDescription": "Medications currently used in the treatment of T2DM have not been shown to modify the progressive decline in beta-cell function that occurs over time. Recent evidence, however, suggests that a new class of anti-diabetic medications, called dipeptidyl peptidase-IV (DPP-IV) inhibitors, may be able to protect beta cells and hence alter the natural history of T2DM. We thus wish to study the effect of sitagliptin (a DPP-IV inhibitor) on the preservation of beta-cell function in patients with T2DM randomized to either (i) sitagliptin and metformin or (ii) placebo and metformin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Type 2 diabetes", "beta-cell function", "sitagliptin", "intensive insulin therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 21, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Sitagliptin 100mg once a day (od) by mouth (po)", "interventionNames": ["Drug: Sitagliptin", "Drug: metformin"]}, {"label": "Placebo arm", "type": "PLACEBO_COMPARATOR", "description": "Placebo once a day (od) by mouth (po)", "interventionNames": ["Drug: Placebo", "Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin", "description": "sitagliptin 100 mg once a day", "armGroupLabels": ["Sitagliptin"], "otherNames": ["januvia"]}, {"type": "DRUG", "name": "Placebo", "description": "placebo once a day", "armGroupLabels": ["Placebo arm"]}, {"type": "DRUG", "name": "metformin", "description": "metformin 1000 mg twice a day (bid) by mouth (po)", "armGroupLabels": ["Placebo arm", "Sitagliptin"], "otherNames": ["glucophage"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR", "description": "Area-under-the-C-peptide-curve (AUCCpep) and area-under-the-glucose-curve (AUCgluc) from 0 to 240 minutes during meal tests were calculated using the trapezoidal rule. Insulin resistance was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Beta-cell function was assessed using the ratio of total AUCCpep to AUCgluc divided by HOMA-IR (AUCCpep/gluc/HOMA-IR), a measure of insulin secretion in the context of ambient insulin sensitivity, analogous to the disposition index and adaptation index. Higher AUCCpep/gluc/HOMA-IR is indicative of better beta-cell function.", "timeFrame": "48 weeks"}], "secondaryOutcomes": [{"measure": "Insulinogenic Index Divided by HOMA-IR at 48 Weeks", "description": "Insulinogenic index was calculated as the incremental change in insulin from 0 to 30 minutes divided by the incremental change in glucose over the same period of time. Insulinogenic index divided by HOMA-IR provides an additional measure of beta-cell function. A higher value indicates better beta-cell function", "timeFrame": "48 weeks"}, {"measure": "Fasting Blood Glucose at 48 Weeks", "timeFrame": "48 weeks"}, {"measure": "Area-under-the-glucose-curve (AUCglucose) on Meal Test at 1 Year", "timeFrame": "1 year"}, {"measure": "Time to Loss of Glycemic Control", "timeFrame": "1 year"}, {"measure": "Proportion of Patients Achieving Sustained Normoglycemia Off Medication at 1-week Post-insulin Therapy", "timeFrame": "1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Men and women between the ages of 30 and 75 inclusive\n2. Physician-diagnosed type 2 diabetes on 0-2 oral hypoglycemic agents\n3. Negative for anti-glutamic acid decarboxylase (anti-GAD_ antibodies (to rule out Latent Autoimmune Diabetes of Adults (LADA)\n4. A1c at screening between 6.5% and 9% inclusive if on no oral hypoglycemic agents or 6.0% and 9.0% inclusive if on 1-2 oral hypoglycemic agents\n\nExclusion Criteria:\n\n1. Current insulin therapy\n2. Type 1 diabetes or secondary forms of diabetes\n3. Any major illness with a life expectancy of \\< 5 years or that may interfere with the patient's participation in the study\n4. Involvement in any other study requiring drug therapy\n5. Renal dysfunction as evidenced by serum creatinine \\>/= 136 umol/L for males or \\>/= 124 umol/L for females or abnormal creatinine clearance (\\< 60 ml/min by Modification of Diet in Renal Disease (MDRD) formula)\n6. Hepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, or previous liver transplant) or transaminases \\> 2.5 times the upper limit of normal\n7. Excessive alcohol consumption, defined as \\> 14 alcoholic drinks per week for males and \\> 9 alcoholic drinks per week for females\n8. Pregnancy or unwillingness to use reliable contraception. Women should not be planning pregnancy for the duration of the study. Reliable contraception includes: birth control pill, intra-uterine device, abstinence, tubal ligation, partner vasectomy, or condoms with spermicide. Any women who miss a menstrual period or think that they may be pregnant must have a pregnancy test as soon as possible\n9. History of serious arrhythmia or atrioventricular block on baseline electrocardiogram\n10. Uncontrolled hypertension (systolic blood pressure \\> 180 mm Hg or diastolic blood pressure \\> 110 mm Hg)\n11. Unwillingness to undergo multiple daily insulin injection therapy for 4 weeks\n12. Unwillingness to perform capillary blood glucose monitoring at least 4 times per day during intensive insulin therapy", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bernard Zinman, MD", "affiliation": "Leadership Sinai Centre for Diabetes, University of Toronto", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Ravi Retnakaran, MD", "affiliation": "Leadership Sinai Centre for Diabetes, University of Toronto", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Leadership Sinai Centre for Diabetes", "city": "Toronto", "state": "Ontario", "zip": "M5T 3L9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}]}, "referencesModule": {"references": [{"pmid": "25495067", "type": "DERIVED", "citation": "Stein CM, Kramer CK, Zinman B, Choi H, Opsteen C, Retnakaran R. Clinical predictors and time course of the improvement in beta-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes. Diabet Med. 2015 May;32(5):645-52. doi: 10.1111/dme.12671. Epub 2015 Jan 7."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants underwent prerandomization phase of 4-8 weeks of intensive insulin therapy (IIT) consisting of basal detemir and premeal insulin aspart. Only participants who achieved fasting glucose \\<7.0 mmol/L 1 day after completing IIT were randomized to either sitagliptin 100 mg once daily or matching placebo.", "recruitmentDetails": "Participants were recruited from outpatient clinics at the Leadership Sinai Centre for Diabetes between February 2007 and October 2008.", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po"}, {"id": "FG001", "title": "Placebo", "description": "Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po"}, {"id": "BG001", "title": "Placebo", "description": "Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "21"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.3", "lowerLimit": "45.5", "upperLimit": "69.5"}, {"groupId": "BG001", "value": "60.8", "lowerLimit": "51.3", "upperLimit": "61.4"}, {"groupId": "BG002", "value": "60.9", "lowerLimit": "47.9", "upperLimit": "61.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "14"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "13"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "34.3", "lowerLimit": "27.3", "upperLimit": "42.6"}, {"groupId": "BG001", "value": "32.7", "lowerLimit": "31.0", "upperLimit": "41.1"}, {"groupId": "BG002", "value": "32.7", "lowerLimit": "28.6", "upperLimit": "41.5"}]}]}]}, {"title": "Duration of diabetes", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.8", "lowerLimit": "2.0", "upperLimit": "4.0"}, {"groupId": "BG001", "value": "3.5", "lowerLimit": "2.0", "upperLimit": "8.0"}, {"groupId": "BG002", "value": "3.0", "lowerLimit": "2.0", "upperLimit": "6.0"}]}]}]}, {"title": "HbA1c", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "percent glycosylated hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.2", "lowerLimit": "5.8", "upperLimit": "6.9"}, {"groupId": "BG001", "value": "6.1", "lowerLimit": "5.9", "upperLimit": "6.9"}, {"groupId": "BG002", "value": "6.1", "lowerLimit": "5.8", "upperLimit": "6.9"}]}]}]}, {"title": "Area-Under-The-Curve (C-peptide/glucose) / HOMA-IR", "description": "Area-under-the-C-peptide-curve (AUCCpep) and area-under-the-glucose-curve (AUCgluc) from 0 to 240 minutes during meal tests were calculated by trapezoidal rule. Insulin resistance was assessed by Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Beta-cell function was assessed using the ratio of AUCCpep to AUCgluc divided by HOMA-IR (AUCCpep/gluc/HOMA-IR), a measure of insulin secretion in the context of ambient insulin sensitivity, analogous to the disposition index and Insulin Secretion-Sensitivity Index-2 (ISSI-2). Higher AUCCpep/gluc/HOMA-IR indicates better beta-cell function.", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "index of beta-cell function", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "114.8", "lowerLimit": "76.3", "upperLimit": "208.7"}, {"groupId": "BG001", "value": "126.0", "lowerLimit": "79.8", "upperLimit": "159.8"}, {"groupId": "BG002", "value": "120.0", "lowerLimit": "66.3", "upperLimit": "129.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR", "description": "Area-under-the-C-peptide-curve (AUCCpep) and area-under-the-glucose-curve (AUCgluc) from 0 to 240 minutes during meal tests were calculated using the trapezoidal rule. Insulin resistance was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Beta-cell function was assessed using the ratio of total AUCCpep to AUCgluc divided by HOMA-IR (AUCCpep/gluc/HOMA-IR), a measure of insulin secretion in the context of ambient insulin sensitivity, analogous to the disposition index and adaptation index. Higher AUCCpep/gluc/HOMA-IR is indicative of better beta-cell function.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "index of beta-cell function", "timeFrame": "48 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (orally administered)"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily and metformin 1000 mg twice a day (orally administered)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "80.4", "lowerLimit": "52.5", "upperLimit": "205.6"}, {"groupId": "OG001", "value": "71.2", "lowerLimit": "40.3", "upperLimit": "139.8"}]}]}]}, {"type": "SECONDARY", "title": "Insulinogenic Index Divided by HOMA-IR at 48 Weeks", "description": "Insulinogenic index was calculated as the incremental change in insulin from 0 to 30 minutes divided by the incremental change in glucose over the same period of time. Insulinogenic index divided by HOMA-IR provides an additional measure of beta-cell function. A higher value indicates better beta-cell function", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "index of beta-cell function", "timeFrame": "48 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.9", "lowerLimit": "1.9", "upperLimit": "4.9"}, {"groupId": "OG001", "value": "1.8", "lowerLimit": "1.3", "upperLimit": "2.8"}]}]}]}, {"type": "SECONDARY", "title": "Fasting Blood Glucose at 48 Weeks", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mmol/l", "timeFrame": "48 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.9", "lowerLimit": "5.5", "upperLimit": "7.4"}, {"groupId": "OG001", "value": "6.7", "lowerLimit": "6.0", "upperLimit": "7.9"}]}]}]}, {"type": "SECONDARY", "title": "Area-under-the-glucose-curve (AUCglucose) on Meal Test at 1 Year", "reportingStatus": "NOT_POSTED", "timeFrame": "1 year"}, {"type": "SECONDARY", "title": "Time to Loss of Glycemic Control", "reportingStatus": "NOT_POSTED", "timeFrame": "1 year"}, {"type": "SECONDARY", "title": "Proportion of Patients Achieving Sustained Normoglycemia Off Medication at 1-week Post-insulin Therapy", "reportingStatus": "NOT_POSTED", "timeFrame": "1 year"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po", "seriousNumAffected": 1, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}, {"id": "EG001", "title": "Placebo", "description": "Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)", "seriousNumAffected": 1, "seriousNumAtRisk": 11, "otherNumAffected": 0, "otherNumAtRisk": 11}], "seriousEvents": [{"term": "Generalized rash", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 11}]}, {"term": "Renal tumor", "organSystem": "Renal and urinary disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The modest sample size of this pilot study may have lacked sufficient statistical power to detect an effect on preservation of beta-cell function."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Ravi Retnakaran", "organization": "Leadership Sinai Centre for Diabetes, Mount Sinai Hospital", "email": "rretnakaran@mtsinai.on.ca", "phone": "416-586-4800", "phoneExt": "3941"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}